Updates on HER2-Directed ADCs Across Solid Tumors - Episode 1
Assessing HER2 Status Across Tumor Types
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Video Player is loading.
Video content above is prompted by the following:
- How do HER2 mutations differ from HER2 overexpression and gene amplification in terms of their impact on cancer?
- How can this differ among cancer types?
- What are the incidences of HER2 overexpression across solid tumors? HER2 mutations?
- What is your current practice for testing for HER2? What testing methodologies are used? How do they differ and what can you learn from each?
- What is the difference between HER2 amplification and IHC score? What are best practices to ensure patients with HER2 amplification aren’t missed?
- Does this vary among solid tumors?
- How have levels of HER2 expression changed? What percent of patients typically have HER2-low expression?
- Is what is known about HER2 expression/mutations from research in breast and other cancer types applicable to other solid tumor types? Are there unique aspects to consider?
- How might current understanding of HER2 expression and HER2 mutations in other solid tumors contribute to the development of future targeted therapies or personalized treatment approaches?
